Market News / Story
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
BusinessWire ·
BusinessWire reports: AbCellera ( ) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San Diego, California. Details on AbCellera’s poster presentation at TMS are as follows: Title: Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABCL635, an NK3R monoclonal antibody antagonist for the treatment of vasomotor symptoms: a Phase 1/2 study…